|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
SCIDIR_ocn166344357 |
003 |
OCoLC |
005 |
20231117015044.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
070828s1999 xx o 000 0 eng d |
040 |
|
|
|a OPELS
|b eng
|e pn
|c OPELS
|d OPELS
|d OCLCQ
|d NRU
|d IDEBK
|d OCLCQ
|d OCLCF
|d UKDOC
|d OCLCQ
|d UIU
|d TFW
|d OCLCQ
|d OL$
|d OCLCQ
|d OCLCO
|d COM
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 705542992
|a 742287928
|a 815564946
|a 823113248
|
020 |
|
|
|a 9780080526379
|
020 |
|
|
|a 0080526373
|
020 |
|
|
|a 1281308684
|
020 |
|
|
|a 9781281308689
|
020 |
|
|
|z 9780762300648
|
020 |
|
|
|z 0762300647
|
035 |
|
|
|a (OCoLC)166344357
|z (OCoLC)705542992
|z (OCoLC)742287928
|z (OCoLC)815564946
|z (OCoLC)823113248
|
050 |
|
4 |
|a RS400
|b .A35eb v. 4
|
072 |
|
7 |
|a MMGT
|2 bicssc
|
082 |
0 |
4 |
|a 615/.19
|2 22
|
245 |
0 |
0 |
|a Advances in medicinal chemistry.
|n Volume 4.
|
260 |
|
|
|a [Place of publication not identified] :
|b Elsevier Science,
|c 1999.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
520 |
|
|
|a Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol� (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.
|
505 |
0 |
|
|a Preface. Novel peptide mimetic building blocks and strategies for efficient lead finding. Recent advances in the medicinal chemistry of taxoid anticancer agents. Synthesis and structure-activity relationships of peroxidic antimalarials based on artemisinin. Design of compound libraries for detecting and pursuing novel small molecule leads. A theoretical model of the human thrombin receptor (PAR-1), the first known protease-activated G-protein-coupled receptor. Farnesyl transferase inhibitors: design of a new class of cancer chemotherapeutic agents.
|
588 |
0 |
|
|a Print version record.
|
650 |
|
0 |
|a Pharmaceutical chemistry.
|
650 |
|
2 |
|a Chemistry, Pharmaceutical
|0 (DNLM)D002626
|
650 |
|
6 |
|a Chimie pharmaceutique.
|0 (CaQQLa)201-0028674
|
650 |
|
7 |
|a Pharmaceutical chemistry
|2 fast
|0 (OCoLC)fst01060115
|
700 |
1 |
|
|a Maryanoff, B. E.
|
700 |
1 |
|
|a Reitz, Allen Bernard,
|d 1956-
|
776 |
0 |
8 |
|i Print version:
|a Maryanoff, B.E.
|t Advances in Medicinal Chemistry, Volume 4.
|d Burlington : Elsevier, �1999
|z 9780762300648
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780762300648
|z Texto completo
|